Airavaara M, Parkkinen I, Konovalova J, Albert K, Chmielarz P, Domanskyi A (2020) Back and to the future: from neurotoxin-induced to human Parkinson’s disease models. Curr Protoc Neurosci 91(1):e88

Article  PubMed  Google Scholar 

Al-kuraishy HM, Al-Gareeb AI, Kaushik A, Kujawska M, Ahmed EA, Batiha GES (2023) SARS-CoV-2 infection and Parkinson’s disease: possible links and perspectives. J Neurosci Res 101(6):952–975

Article  CAS  PubMed  Google Scholar 

Al-Kuraishy HM, Al-Gareeb AI, Negm WA, Alexiou A, Batiha GE (2022) Ursolic acid and SARS-CoV-2 infection: a new horizon and perspective. Inflammopharmacology 30(5):1493–1501

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Kuraishy HM, Al-Gareeb AI, Saad HM, Batiha GE (2023a) Long-term use of metformin and Alzheimer’s disease: beneficial or detrimental effects. Inflammopharmacology 31:1–9

PubMed  Google Scholar 

Al-Kuraishy HM, Al-Gareeb AI, Saad HM, Batiha GE (2023b) The potential therapeutic effect of statins in multiple sclerosis: beneficial or detrimental effects. Inflammopharmacology 31:1–12

Article  PubMed  Google Scholar 

Al-Kuraishy HM, Al-Gareeb AI, Selim HM, Alexiou A, Papadakis M, Negm WA and Batiha GE (2023c) Does vitamin D protect or treat Parkinson’s disease? A narrative review. Naunyn-Schmiedeberg's Archives Pharmacol 396:1–8

Google Scholar 

Alsubaie N, Al-Kuraishy HM, Al-Gareeb AI, Alharbi B, De Waard M, Sabatier J-M, Saad HM, Batiha GE-S (2022a) Statins use in Alzheimer disease: bane or boon from frantic search and narrative review. Brain Sci 12(10):1290

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alsubaie N, Al-Kuraishy HM, Al-Gareeb AI, Alharbi B, De Waard M, Sabatier JM, Saad JM, Batiha GE (2022b) Statins use in Alzheimer disease: bane or boon from frantic search and narrative review. Brain Sci 12(10):1290

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bagheri H, Ghasemi F, Barreto GE, Sathyapalan T, Jamialahmadi T, Sahebkar A (2020) The effects of statins on microglial cells to protect against neurodegenerative disorders: a mechanistic review. BioFactors 46(3):309–325

Article  CAS  PubMed  Google Scholar 

Batiha GE-S, Al-Kuraishy HM, Al-Gareeb AI, Elekhnawy E (2023) SIRT1 pathway in Parkinson’s disease: a faraway snapshot but so close. Inflammopharmacology 31(1):37–56

Article  CAS  PubMed  Google Scholar 

Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B (2014) A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol 71(5):543–552

Article  PubMed  Google Scholar 

Björkhem I, Lövgren-Sandblom A, Leoni V, Meaney S, Brodin L, Salveson L, Winge K, Pålhagen S, Svenningsson P (2013) Oxysterols and Parkinson’s disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease. Neurosci Lett 555:102–105

Article  PubMed  Google Scholar 

Blauwendraat C, Nalls MA, Singleton AB (2020) The genetic architecture of Parkinson’s disease. The Lancet Neurology 19(2):170–178

Article  CAS  PubMed  Google Scholar 

Braak H, Del Tredici K (2017) Neuropathological staging of brain pathology in sporadic Parkinson’s disease: separating the wheat from the chaff. J Parkinsons Dis 7(s1):S71–S85

Article  PubMed  PubMed Central  Google Scholar 

Butterfield DA, Barone E, Mancuso C (2011) Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. Pharmacol Res 64(3):180–186

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bykov K, Yoshida K, Weisskopf MG, Gagne JJ (2017) Confounding of the association between statins and Parkinson disease: systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 26(3):294–300

Article  CAS  PubMed  Google Scholar 

Cerri S, Mus L, Blandini F (2019) Parkinson’s disease in women and men: what’s the difference? J Parkinsons Dis 9(3):501–515

Article  PubMed  PubMed Central  Google Scholar 

Chung SJ, Yoo HS, Lee YH, Lee PH, Sohn YH (2019) Heterogeneous patterns of striatal dopamine loss in patients with young-versus old-onset Parkinson’s disease: impact on clinical features. J Mov Disord 12(2):113

Article  PubMed  PubMed Central  Google Scholar 

Clementino AR, Marchi C, Pozzoli M, Bernini F, Zimetti F, Sonvico F (2021) Anti-inflammatory properties of statin-loaded biodegradable lecithin/chitosan nanoparticles: a step toward nose-to-brain treatment of neurodegenerative diseases. Front Pharmacol 12:716380

Article  CAS  PubMed  PubMed Central  Google Scholar 

Consonni A, Miglietti M, De Luca CMG, Cazzaniga FA, Ciullini A, Dellarole IL, Bufano G, Di Fonzo A, Giaccone G, Baggi F (2022) Approaching the gut and nasal microbiota in Parkinson’s disease in the era of the seed amplification assays. Brain Sci 12(11):1579

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dickson DW (2018) Neuropathology of Parkinson disease. Parkinsonism Relat Disord 46:30–33

Article  Google Scholar 

Eriksson I, Nath S, Bornefall P, Giraldo AMV, Öllinger K (2017) Impact of high cholesterol in a Parkinson’s disease model: Prevention of lysosomal leakage versus stimulation of α-synuclein aggregation. Eur J Cell Biol 96(2):99–109

Article  CAS  PubMed  Google Scholar 

Fabelo N, Martín V, Santpere G, Marín R, Torrent L, Ferrer I, Díaz M (2011) Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson’s disease and incidental Parkinson’s disease. Mol Med 17(9):1107–1118

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fang F, Zhan Y, Hammar N, Shen X, Wirdefeldt K, Walldius G, Mariosa D (2019) Lipids, apolipoproteins, and the risk of Parkinson disease: a prospective cohort study and a mendelian randomization analysis. Circ Res 125(6):643–652

Article  CAS  PubMed  Google Scholar 

Fortin DL, Troyer MD, Nakamura K, Kubo SI, Anthony MD, Edwards RH (2004) Lipid rafts mediate the synaptic localization of α-synuclein. J Neurosci 24(30):6715–6723

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fukui K, Ferris HA, Kahn CR (2015) Effect of cholesterol reduction on receptor signaling in neurons. J Biol Chem 290(44):26383–26392

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heras-Garvin A, Stefanova N (2020) From synaptic protein to prion: the long and controversial journey of α-synuclein. Front in Synaptic Neurosci 12:584536

Article  CAS  Google Scholar 

Hou X, Watzlawik JO, Fiesel FC, Springer W (2020) Autophagy in Parkinson’s disease. J Mol Biol 432(8):2651–2672

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J (2008a) Total cholesterol and the risk of Parkinson disease. Neurology 70(21):1972–1979

Article  CAS  PubMed  Google Scholar 

Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J (2008b) Total cholesterol and the risk of Parkinson disease. Neurology 70(21):1972–1979

Article  CAS  PubMed  Google Scholar 

Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC, Xiang D, Murrow RW, Wang YZ, Poole C (2007) Lower low-density lipoprotein cholesterol levels are associated with Parkinson’s disease. Movem Disord 22(3):377–381

Article  Google Scholar 

Huang X, Sterling NW, Du G, Sun D, Stetter C, Kong L, Zhu Y, Neighbors J, Lewis MM, Chen H, Hohl RJ (2019) Brain cholesterol metabolism and Parkinson’s disease. Mov Disord 34(3):386–395

Article  PubMed  PubMed Central  Google Scholar 

Hussien NR, Al-Niemi MS, Al-Kuraishy HM, Al-Gareeb AI (2021) Statins and covid-19: The neglected front of bidirectional effects. J Pak Med Assoc 71(8):133

Google Scholar 

Javed H, Meeran MN, Azimullah S, Bader Eddin L, Dwivedi VD, Jha NK, Ojha S (2020) α-Bisabolol, a dietary bioactive phytochemical attenuates dopaminergic neurodegeneration through modulation of oxidative stress, neuroinflammation and apoptosis in rotenone-induced rat model of Parkinson’s disease. Biomolecules 10(10):1421

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jeong SH, Lee HS, Chung SJ, Yoo HS, Jung JH, Baik K, Lee YH, Sohn YH, Lee PH (2021) Effects of statins on dopamine loss and prognosis in Parkinson’s disease. Brain 144(10):3191–3200

Article  PubMed  Google Scholar 

Jeong SM, Jang W, Shin DW (2019) Association of statin use with Parkinson’s disease: dose–response relationship Mov. Disorders 34(7):1014–1021

Article  CAS  Google Scholar 

Jiang H, Bai X (2022) Apolipoprotein AI mimetic peptides (ApoAI MP) improve oxidative stress and inflammatory responses in Parkinson’s disease mice. Front Pharmacol 13:966232

Article  CAS  PubMed